Project Grant R01AA033349
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $478K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- The National Institute on Alcohol Abuse and Alcoholism awarded The University of Texas Southwestern Medical Center $702,746 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate epigenetic regulation of endogenous retroviruses and alcohol-associated liver disease. The research will define mechanisms by which alcohol metabolism induces endogenous retrovirus (ERV) reactivation, reverse transcription, and innate immune activation, focusing on metabolic and...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), a division of the Department of Health and Human Services National Institutes of Health, awarded Yale University $663,419 on August 11, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate liver sinusoidal endothelial cell (LSEC) inflammation in alcohol-associated liver disease. The research addresses mechanisms by which alcohol disrupts LSEC homeostasis through two converging pathways: IL6 trans-signaling mediated...
- The National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health within the Department of Health and Human Services, awarded $682,736 to Beth Israel Deaconess Medical Center, Inc. on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate myeloid-derived suppressor cells (MDSCs) in alcohol-associated steatohepatitis. The award funds research characterizing MDSC phenotypes and immunoregulatory capacity in alcohol-associated hepatitis...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Administrators Of Tulane Educational Fund (doing business as Tulane University) $401,626 on September 26, 2025, under the Alcohol Research Programs (CFDA 93.273) to investigate plasma membrane rupture in alcohol-associated hepatitis. The recipient will determine the role of plasma membrane rupture (PMR) in alcohol-associated liver disease and investigate the mechanism by which cholestasis promotes hepatocellular PMR in that...
- The National Institute on Alcohol Abuse and Alcoholism awarded Beth Israel Deaconess Medical Center, Inc. $177,736 on August 17, 2026, under the Alcohol Research Programs (CFDA 93.273) to support a postdoctoral researcher's career development in understanding the role of neutrophil extracellular traps (NETs) in alcohol-induced acute-on-chronic liver failure. The award funds a two-year mentored research program spanning August 17, 2026, through July 31, 2028, based in Boston, Massachusetts. The...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $456,096 under Project Grant R21AA031889 on September 10, 2025, to explore the role of hepatocyte inflammasome in alcoholic liver disease (AALD). The research investigates how caspase-1, a component of the inflammasome pathway, influences AALD pathophysiology in hepatocytes. The project employs liver-specific genetic deletion models using albumin-cre mice, bulk RNA sequencing, proteomic analysis, and in vitro...
- The National Institute on Alcohol Abuse and Alcoholism awarded Yale University $1.321 million on September 16, 2025, under the Alcohol Research Programs (CFDA 93.273) to investigate ITPR3 and aberrant mitochondrial calcium signaling in alcoholic hepatitis. The project examines how altered mitochondrial calcium signaling contributes to the development of alcohol-associated hepatitis (AAH), a severe complication of alcohol-associated liver disease with short-term mortality ranging from 20 to 50...
- The National Institute on Alcohol Abuse and Alcoholism awarded the University of Kansas Medical Center Research Institute, Inc. $301,070 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate mechanisms that regulate hepatocyte fate during recovery from alcohol-associated hepatitis. The research addresses the pathogenesis of alcohol-associated liver disease, which progresses from simple steatosis to severe forms including alcoholic hepatitis, fibrosis,...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Trustees of Columbia University in the City of New York $2,359,200 on July 15, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate the regulation of hepatocyte functions by hepatic stellate cells in steatotic liver diseases, including alcohol-associated liver disease, metabolic dysfunction-associated fatty liver disease, and mixed forms. The research characterizes an R-spondin 3-mediated hepatic stellate cell...
- The National Institute on Alcohol Abuse and Alcoholism awarded the University of Texas at Dallas $555,966 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate vagus nerve stimulation and cholinergic anti-inflammatory pathways in alcohol-associated liver disease pathogenesis. The funded research examines whether left cervical vagus nerve stimulation protects against alcohol-associated liver disease through activation of the α7 nicotinic acetylcholine receptor...